GeneDx Swings to $17.7M Q2 Loss as Commercial Spend Surges; Fabric Genomics Impairment Hits $31.3M
WGS has more than doubled off its 52-week low of $32.21.
Summary
GeneDx reported a $17.7M Q2 net loss, a $31.3M Fabric Genomics impairment, and surging costs. Post-quarter financing at a discount to market highlights liquidity pressure.
Key Events · Earnings and Guidance · WGS
-
Q2 Net Loss of $17.7M
GeneDx swung to a $17.7M net loss in Q2 2026 from a $10.8M profit a year ago, as SG&A expenses surged 62% to $76.0M. Six-month net loss reached $81.1M.
-
$31.3M Fabric Genomics Impairment
A non-cash impairment charge of $31.3M was recorded in Q1 2026 for goodwill and intangible assets tied to the Fabric Genomics acquisition, reflecting lowered revenue and profitability expectations.
-
Revenue Growth Offset by Reimbursement Pressure
Total revenue rose 11% to $114.4M, driven by a 32% increase in exome and genome test volumes. However, average reimbursement rates declined 12%, partially offsetting volume gains.
-
Material Weakness Remains Unremediated
The previously disclosed material weakness in IT general controls related to segregation of duties in program change management has not been fully remediated as of June 30, 2026.
Analysis · WGS · Industrial Applications And Services
GeneDx's Q2 results reveal a sharp reversal from profitability a year ago, driven by a 62% jump in SG&A as the company aggressively expands its commercial team. A $31.3 million non-cash impairment on the Fabric Genomics acquisition underscores the failed integration and strategic missteps. While exome and genome test volumes grew 32%, average reimbursement rates fell 12%, squeezing margins. The unremediated material weakness and new securities class actions add governance and legal overhangs. Post-quarter, the company amended its Blackstone loan for an extra $50 million and sold $5 million in stock at $61 per share — a discount to the current $77 price — signaling urgent cash needs.
At the time of this filing, WGS was trading at $77.01 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $2B. The 52-week trading range was $32.21 to $170.87. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.